Company profile
ARTIVA BIOTHERAPEUTICS, INC.
NASDAQ:ARTVBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AB-101 | phase1_2 | — | 3 | active |
| ANPOCOGIN | phase1_2 | — | 1 | withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05678205 | phase1_2 | withdrawn | 2023-08-01 | 2027-04-01 | Artiva Biotherapeutics, Inc. | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors |
| NCT04673617 | phase1_2 | completed | 2021-03-29 | 2025-10-06 | Artiva Biotherapeutics, Inc. | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT06265220 | phase1 | active_not_recruiting | 2024-04-03 | 2027-08-01 | Artiva Biotherapeutics, Inc. | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus |
| NCT06991114 | phase2 | recruiting | 2025-07-09 | 2028-01-01 | Artiva Biotherapeutics, Inc. | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. |
FDA applications (0)
No records yet.